



NOV 3 2006

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Alveolus, Inc.  
% Mr. Donald Canal  
Vice President RA/QA  
9013 Perimeter Woods Drive  
Suite A  
Charlotte, North Carolina 28216

Re: K033990  
Trade/Device Name: Alveolus, TB-STST<sup>TM</sup> Tracheobronchial Stent System  
Regulation Number: 21 CFR 878.3720  
Regulation Name: Tracheal prosthesis  
Regulatory Class: II  
Product Code: JCT  
Dated: April 9, 2004  
Received: April 12, 2004

Dear Mr. Canal:

This letter corrects our substantially equivalent letter of May 12, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set


Page 2 - Mr. Donald Canal

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Mark N. Melkerson

Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

## Indications for Use

510(k) Number (if known): K033990

Device Name: Alveolus, TB-STSTM Tracheobronchial Stent System

### Indications For Use:

The Alveolus TB-STSTM Tracheobronchial Stent System is indicated for use in the treatment of tracheobronchial strictures and airway compression (stenosis) produced by malignant neoplasms. Because the device is removable it may also be used to treat conditions such as tracheo-esophageal fistula resulting from malignancies and strictures resulting from surgical anastomosis of the airway in patients with malignancies.

Prescription Use    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use    
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

510(k) Number K033990

## SUMMARY OF SAFETY AND EFFECTIVENESS

### General Company Information

Name: Alveolus, Inc.  
Contact: Don Canal  
  
Address: 9013 Perimeter Woods Dr  
Suite A  
Charlotte, NC 28216  
  
Telephone: (704) 926 – 4850  
Fax: (704) 926 – 4895

### General Device Information

Product Name: TB-STSTM Tracheobronchial Stent System  
Classification: "Tracheal Prosthesis", Product code: JCT  
Class II

### Predicate Devices

Alveolus, Inc. TB-STSTM Tracheobronchial Stent System  
[510(k) Numbers K030947]

Boston Scientific Corp. Inc. UltraflexTM Tracheobronchial Stent System  
[501(k) Number K963241]

Vascular Architects, Inc. aSpireTM Covered Stent and CONTROLLED  
EXPANSION™ Delivery System [510(k) Number K003173 and K012544]

### Description

The Alveolus Tracheobronchial Stent Technology System is comprised of two components: the radiopaque stent and the delivery system. The nitinol stent is completely covered with a biocompatible polyurethane (ChronoFlex™) membrane and is self-expanding. The inner lumen of the expanded stent is coated with a hydrophilic polymer to improve lubricity. The stent expansion results from the mechanical properties of the metal and the proprietary geometry. The stent is designed with a slightly larger diameter near the distal and proximal ends to minimize the possibility of migration. The stent ends are slightly vaulted inwardly in order to minimize possible airway injury from the stent edges. The overall stent geometry is designed to maintain a constant length over the entire range of possible diameters. As a result of this



unique design the stent has virtually no foreshortening, thus facilitating the selection of the appropriate stent length.

### **Indications**

The Alveolus TB-STST<sup>TM</sup> Tracheobronchial Stent System is indicated for use in the treatment of tracheobronchial strictures and airway compression (stenosis) produced by malignant neoplasms. Because the device is removable it may also be used to treat conditions such as tracheo-esophageal fistula resulting from malignancies and strictures resulting from surgical anastomosis of the airway in patients with malignancies.

### **Substantial Equivalence**

This submission supports the position that the Alveolus Tracheobronchial Stent is substantially equivalent to a number of previously cleared devices, including the Alveolus TB STS<sup>TM</sup> Tracheobronchial Stent System previously approved [510(k) K030947], the Boston Scientific Corp. Inc. Ultraflex<sup>TM</sup> Tracheobronchial Stent System [501(k) Number K963241], the Vascular Architects, Inc. aSpire<sup>®</sup> Covered Stent<sup>®</sup> [510(k) Number K003173 and K012544].

The 510(k) Notice contains summaries of physical test results, and biocompatibility test results as specified in the FDA Guidance Document for Testing Esophageal and Tracheal Prostheses (April 28, 1998).

The data presented demonstrate that the device is biocompatible and is suitable for its indicated use.

The single-patient-use components of the TB-STST<sup>TM</sup> Tracheobronchial Stent System are provided sterile.

Alveolus Inc. believes that the information provided establishes that similar legally marketed devices have been used for the same clinical applications as the Alveolus Tracheobronchial Stent. The materials from which the Alveolus device is fabricated have an established history of use in clinical applications, and the devices produced by Alveolus have been tested in accordance with applicable FDA guidelines.